Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
暂无分享，去创建一个
D. Provencher | J. Ledermann | M. Birrer | I. Vergote | S. Pignata | U. Matulonis | J. Sehouli | N. Colombo | P. Ottevanger | G. Sonke | A. Santin | R. Shapira-Frommer | A. Oaknin | F. Raspagliesi | A. Lisyanskaya | K. Katchar | J. Ruman | V. Rudaitis | A. González-Martín | Zhen Wang